Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thromboembolism | D013923 | — | — | — | 1 | 2 | 4 | 4 | 11 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 1 | 1 | 3 | 4 | 9 |
Thrombosis | D013927 | — | — | — | 2 | 1 | 3 | 2 | 8 |
Venous thrombosis | D020246 | — | I82.40 | — | 1 | 1 | 3 | 1 | 6 |
Embolism | D004617 | — | — | — | 1 | 1 | 1 | 2 | 5 |
Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | — | 1 | 1 | 1 | 3 |
Neoplasms | D009369 | — | C80 | — | — | — | 1 | 1 | 2 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | 1 | 2 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | — | 1 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | — | N19 | — | — | 1 | — | 2 | 3 |
Diabetic foot | D017719 | EFO_1001459 | — | — | 2 | 2 | — | — | 2 |
Ulcer | D014456 | MPATH_579 | — | — | 2 | 2 | — | — | 2 |
Foot ulcer | D016523 | — | — | — | 2 | 2 | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | 1 | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
Headache disorders | D020773 | EFO_0009550 | G44 | — | — | 1 | — | — | 1 |
Headache | D006261 | — | R51 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Embolism and thrombosis | D016769 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Clear cell sarcoma | D018227 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | — | — | — | — | 1 | 1 |
Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | — | — | — | 1 | 1 |
Habitual abortion | D000026 | EFO_1000954 | N96 | — | — | — | — | 1 | 1 |
Fetal death | D005313 | — | — | — | — | — | — | 1 | 1 |
Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Dalteparin sodium |
INN | dalteparin sodium |
Description | Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.
|
Classification | Oligosaccharide |
Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | 67109 |
ChEMBL ID | CHEMBL1201460 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06779 |
UNII ID | 12M44VTJ7B (ChemIDplus, GSRS) |